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http://dxObjectives: We sought to investigate if autologous freshly isolated regulatory T cells (Tregs) provide a
protective and supportive role when cotransplanted with mesenchymal stem cells (MSCs).
Methods: In a porcine model of chronic ischemia, autologous MSCs were isolated and expanded ex vivo for 4
weeks. Autologous Treg cells were freshly isolated from 100 mL peripheral blood and purified by fluorescence-
activated cell sorting. MSCs and Treg cells were then cotransplanted into the chronic ischemic myocardium of
Yorkshire pigs by direct intramyocardial injection (1.23 108 MSCs plus an average of 1.5 million Treg cells in
25 injection sites). Animals were killed 6 weeks postinjection to study the fate of the cells and compare the effect
of combined MSCs þ Treg cells transplantation versus MSCs alone.
Results: The coinjection of MSCs along with Tregs was safe and no deleterious side effects were observed. Six
weeks after injection of the cell combination, spherical MSCs clusters with thin layer capsules were found in the
injected areas. In animals treated with MSCs only, the MSC clusters were less organized and not encapsulated.
Immunofluorescent staining showed CD25þ cells among the CD90þ (MSC marker) cells, suggesting that the
injected Treg cells remained present locally, and survived. Factor VIIIþ cells were also prevalent suggesting
new angiogenesis. We found no evidence that coinjections were associated with the generation of cardiac
myocytes.
Conclusions: The cotransplantation of Treg cells with MSCs dramatically increased the MSC survival rate,
proliferation, and augmented their role in angiogenesis, which suggests a new way for future clinical application
of cell-based therapy. (J Thorac Cardiovasc Surg 2014;148:1131-7)Cell-based therapy using either mesenchymal stem cells
(MSCs) or induced pluripotent stem cells has been broadly
used in animal models of myocardial ischemia or infarction
to improve heart function or to regenerate damaged myo-
cytes.1-6 We previously reported that autologous transplan-
tation of MSCs led to improvement in global left ventricular
function and regional wall thickening in an ischemic
myocardium.7 However the issue of cell survival after
transplantation is still a major obstacle for cell-based therapy.
Efforts have been focused on stem cell gene manipulation8,9
or using materials such as hydrogel10 that would help to
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The Journal of Thoracic and CarThese efforts have been shown to be of reliable benefit in
animal models; however, when used clinically, potential risks
or side effects cannot be excluded followinggenemanipulation
or the use of adjunct materials for improved stem cell survival.
Studies have shown that CD4þCD25hiFoxP3þ T regulatory
(Treg) cells have the potential to suppress inflammation,
promote angiogenesis, induce tolerance, and provide a
favorable environment for cellular engraftment.11,12 We
sought to investigate if autologous Treg cells provide a
protective and supportive role when cotransplanted with
MSCs in an animal model of chronic ischemia.T
XMATERIAL AND METHODS
Animals
The experimental protocol was approved by the Institutional Animal
Care and Use Committee of the National Heart, Lung, and Blood Institute,
and the investigation conformed to the Guide for the Care and Use of
Laboratory Animals (National Academy Press, 1996, Washington, DC).
Yorkshire domestic pigs, initially weighing 15 to 20 kg, were selected
for this study. All animals were housed 1 per cage and allowed free access
to water and commercial pig food.
Study Design
Fifteen animals underwent a small left thoracotomy under general
anesthesia and had placement of an ameroid constrictor around thediovascular Surgery c Volume 148, Number 3 1131
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G-CSF ¼ granulocyte colony-stimulating factor
LCX ¼ left circumflex artery
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PBMC ¼ peripheral blood mononuclear cells
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Xproximal left circumflex artery (LCX) to create a model of chronic
myocardial ischemia. At this first operation, bone marrow (about 15 mL)
was harvested for ex vivo stem cell expansion. Four weeks later, a second
left thoracotomy was performed in each animal. The circumflex territory
(ischemic zone) was exposed and injected with ex vivo expanded MSCs
that were mixed with freshly isolated Tregs in 7 animals. Six animals
received only MSCs as control. Six weeks following cell injection, all
animals were killed, and the hearts were harvested for histopathologic
evaluation (Figure 1).
Chronic Ischemia Model
All animals were anesthetized and underwent a left-sided thoracotomy.
The pericardial sac was partially opened to facilitate dissection and
visualization of the LCX as it branches from the left coronary artery. After
LCX exposure, a 2.5- to 3.5-mm titanium-encased ameroid was placed
around the proximal LCX. The pericardial sac was then closed to minimize
adhesion formation. The ameroid constrictor gradually occludes the LCX
over a period of 3 to 4 weeks resulting in a region of myocardial ischemia
of the left ventricle.13 Fifteen to 20 mL bone marrow was aspirated during
the ameroid placement procedure while the animals were still under
general anesthesia. To help prevent arrhythmias, all animals were given
amiodarone preoperatively beginning 5 to 7 days before the second surgery,
which was continued until harvest.
Preparation and Culture of Bone Marrow–Derived
Cells
Using aseptic technique, bone marrow was aspirated from either the
iliac crest or tibia of the pig into a syringe containing preservative-free
heparin. Peripheral red blood cells were separated by gradient centrifuga-
tion using lymphocyte separation liquid. The middle layered cells were
collected and divided into 2 populations: 1 population was cultured in
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and
13 penicillin-streptomycin in a density of 106/cm2 at 37C with 5%
carbon dioxide in T-75 culture flasks without coating. When the
attached cells reached confluence, they were split and expanded for 3 to
4 passages. Cells were assessed for cell surface markers, multipotency of
differentiation, and karyotype analysis.
Isolation and Purification of Tregs
Fresh autologous Tregs were isolated and purified the same day that the
animals were scheduled for MSC injections. Peripheral blood (100 mL)
obtained from each animal with chronic left myocardial ischemia was
diluted at a ratio of 1:2 with phosphate buffered saline (PBS) and
centrifuged over a ficoll-hypaque gradient to obtain peripheral blood
mononuclear cells (PBMCs). The remaining red blood cells in the
PBMC solution were lysed by 13 PharmLyse (BD Biosciences, Mountain-
view, Calif) according to the manufacturer’s instructions and then washed
twice with PBS. The isolated PBMCs from each animal were then
incubated with the mouse anti pig CD4 (clone 74-12-4; BD Biosciences)
and mouse anti-pig CD25 (clone K231.3B2; GeneTex; Irvine, Calif)
antibodies for 30 minutes. After the incubation, PBMCs were washed 21132 The Journal of Thoracic and Cardiovascular Surtimes with PBS and then incubated with secondary antibody-goat
antimouse anti-immunoglobulin G1conjugated with phycoerythrin
(SBA, Birmingham, Ala) for 30 minutes and washed 2 times with PBS.
The Treg cells (CD4þCD25þ) were then purified by flow cytometry cell
sorting using FACSAria (BDBiosciences) cell sorters. Dead cell exclusion
was done with 7-aminoactinomycin D.
Treatment of Ischemic Zone With Bone Marrow–
Derived MSCs Plus Peripheral Blood-Derived Tregs
Four weeks following ameroid placement, ex vivo expanded autologous
MSCs (1.23 107) were mixed with freshly isolated and purified peripheral
blood derived Tregs (average of 1.5 3 106) in 2.5 mL saline. This cell
mixture was injected intramyocardially in each animal with a 25-gauge
needle (with an injection depth of 0.5 mm) around the left myocardial
ischemic zone (25 injection sites, 100 mL in each site). As controls,
6 animals underwent same ameroid placement and bone marrow extraction
procedure, but received MSCs only.
Histologic and Immunohistochemistry Analysis
After recipient pig euthanasia, transmyocardial tissue clumps of the
suture marked injection area within ischemic (LCX territory) myocardium,
ischemic area with no injection, or nonischemic (right ventricle territory)
myocardium were cut into 5 3 5 mm-thick pieces. These tissue sections
were collected in cassettes and fixed with 10% buffered formalin for
paraffin embedding or embedded in optimal cutting temperature medium
for frozen sections with no fixation. The tissue clumps from the injected
areas were further cut into 4 pieces and collected separately to track the
injected cells. Paraffin-embedded sections were stained with hematoxylin
and eosin and Masson trichrome for morphologic analysis. Immunohisto-
chemical or immunofluorescent staining was performed using the mouse
monoclonal antihuman antibodies (which cross-react with pig) to CD90,
(BD Biosciences), and mouse anti-pig CD25. The incubations of the pri-
mary antibodies were followed by detections of fluorescein isothiocyanate
or rhodamine conjugated with antimouse immunoglobulin G and the nuclei
were labeled with 40, 6-diamidino-2-phenylindole.RESULTS
Determination of Morphology and Surface
Expression of MSCs and Tregs
Bone marrow–derived MSCs showed uniformed
fibroblast-like morphology. After 4 weeks of ex vivo
expansion, the total number of cells reached 1.2 3 108.
Fluorescence-activated cell sorting analysis at passage 4
revealed cells strongly positive for cell surface expression
of CD44 and CD90, but negative for CXCR4, CD34,
C-kit, CD144, CD54, CD45, and CD31 surface markers.
These results indicate that bone marrow–derived stem cells
are MSCs, instead of endothelial progenitor cells. Positive
adipogenesis and osteogenesis testing confirmed the
multipotency of these cells. The normal karyotype pattern
ensured the MSCs were not transformed over the 4 weeks
of ex vivo expansion. The purity of peripheral blood derived
freshly isolated autologous Tregs was >95% after cell
sorting (Figure 2).Animal Survival
In our preliminary study, 2 animals died of heart
failure following ameroid placement before cell treatment,gery c September 2014
FIGURE 1. Diagram showing the experimental timeline from ameroid placement, mesenchymal stem cells and regulatory T cells injection, to the end of
the experiment. MSC, Mesenchymal stem cell; LCX, left circumflex artery; LAD, left anterior descending artery.
Zhou et al Cardiothoracic Transplantation and Mechanical Circulatory Supportpossibly due to myocardial infarctions or arrhythmias. One
animal in the MSC plus Treg group died after cell injection
due to a surgical wound infection. Six animals survived to
the scheduled euthanasia in both groups. All animals
following MSCs plus Tregs, or MSCs-only injection
showed no signs of severe side effects related to cell
injection.Histologic Analysis
Six weeks after the combined cell therapy (MSCs plus
Tregs), no observable fibrosis was found on histopathology.
Under light microscopy, spherical MSC clusters with thin
layers (15-20 mm in thickness) of capsules were found
in the injected areas in all six treated animals (Figure 3).
These cell clusters can be found in all sections (with 2- to
6-in each section) under low power (12.53) magnification.
In contrast to animals treated with Treg andMSC injections,
animals that received only MSC injections had cell clusters
in all sections with similar numbers in each section;FIGURE 2. Freshly isolated pig natural regulatory T cells were purified with
CD25þ cells before sorting. Right, Both CD4þ and CD25þ regulatory T cells
SSC, Side-scattered light; FSC, forward-scattered light.
The Journal of Thoracic and Carhowever, these MSC clusters were less organized and not
encapsulated (Figure 4). This finding may suggest that
with Treg cotransplantation, MSC survival was increased.
Additionally, MSCs may also proliferate locally in the pres-
ence of Tregs. Immunofluorescent staining showed that the
CD25þ cells were found among the CD90þ cells, suggest-
ing that even after 6 weeks of injection, Treg cells remained
present locally, and survived (Figure 5). No MSC clusters
were found in the noninjected ischemic or normal
myocardial area. The CD25þ cells were also not detectable
in the MSC only sections. Factor VIII and smooth muscle
actin positive cells were also prevalent around the cell
cluster area suggesting the formation of new vessels
(Figure 6). We found no evidence that coinjections were
associated with the generation of new cardiac myocytes.DISCUSSION
Clinical application of stem cell therapy in cardiovascu-
lar disease has been used during the past decade in severalflow cytometry cell sorting. Left, Gated lymphocytes. Center, CD4þ and
after sorting and ready for cotransplantation with mesenchymal stem cells.
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FIGURE 3. Hematoxylin and eosin staining of a representative animal at 6 weeks after mesenchymal stem cells plus regulatory T cells injection showing
spherical cell clusters with thin layers of capsules in frozen and paraffin-embedded sections. A, Arrow indicates the capsule around the cell clump (3100) in
a frozen section. B, Higher magnification of (A) (3400). C, Three cell clusters were found inside myocardium (3100) in a paraffin-embedded section.
D, Higher magnification of (C) (3200).
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Xdifferent ways: through the route of intracoronary injection
using balloon/catheter devices, intravenous injection,
and/or using granulocyte colony-stimulating factor
(G-CSF) to stimulate the mobilization of bone marrow cellsFIGURE 4. Hematoxylin and eosin staining of a representative animal at 6
(paraffin-embedded sections). A, Cell clusters were found in the border area o
C, A cell cluster was found inside myocardium (3100). D, Higher magnificati
1134 The Journal of Thoracic and Cardiovascular Surinto the circulation.14-24 Beneficial effects or functional
improvements have been reported using these cell-based
therapies. However it is obvious that large portions of
intracoronary injected cells flow into the bloodstream andweeks after mesenchymal stem cells injection without regulatory T cells
f epi- and myocardium (3100). B, Higher magnification of (A) (3200).
on of (C) (3200). Arrows indicate the cell clusters.
gery c September 2014
FIGURE 5. Immunofluorescent staining of CD25 (green), CD90 (red), and 6-diamidino-2-phenylindole (blue) in frozen section at 6 weeks after
mesenchymal stem cells plus regulatory T cells injection. A, CD25þ (regulatory T cells marker) cells were found inside the cell cluster with CD90þ
(mesenchymal stem cell marker) cells (3200). B, Higher magnification of (A) (3400). Arrows indicate CD90þ cells and arrowheads indicate CD25þ cells.
C, Stained with no first antibodies (control). D, Higher magnification of (C).
Zhou et al Cardiothoracic Transplantation and Mechanical Circulatory Supportonly a small number of the cells actually migrate into and
remain in the ischemic myocardium. The majority of
nonexpanded mononuclear cells from bone marrow areFIGURE 6. Immunofluorescent staining of Factor VIII (green), smooth muscl
weeks after mesenchymal stem cells plus regulatory T cells injection. A, Increa
staining around the spherical cell cluster compared with (B) (no cluster area). C
(no antibodies were used). Arrows indicate cell clusters. Magnifications are 31
The Journal of Thoracic and Carhematopoietic lineage cells, so that the beneficial effects
created by these cells are limited. The intracoronary
injection is only applicable for nonex vivo expanded cellse actin (red), and 6-diamidino-2-phenylindole (blue) in frozen section at 6
sed capillary density suggested by Factor VIIIþ and smooth muscle actin
, A typical spherical cell cluster from another animal. D, Negative control
00.
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X(or after short expansion times of 4 days or fewer), because
the cell size of expanded cells are much bigger than
nonexpanded cells (10-15 mm vs 5 mm in diameter).
G-CSF mobilized cells are also heterogeneous, only a small
fraction is endothelial progenitors and may or may not
contain any MSCs. Therefore the above 2 methods of
using nonexpanded bone marrow–derived cells or G-CSF
mobilized cells will dramatically limits their benefits. We
recently used direct injection of expanded MSCs into the
ischemic area to facilitate the ability to determine both
the beneficial effects and the fate of the injected cells.7
Because this method entails direct injection to target tis-
sues, there are no issues related to homing. Unfortunately,
this is not a perfect technique either, because the amount
of MSCs is also reduced dramatically following injection.
This loss in cell number occurs in 2 ways: loss immediately
after injection due to continuous myocardial contraction
and gradual loss from the treated area over the course of
follow up due to a limited self-renewing rate.25 Therefore,
several ways have been used to change the behavior of
the stem cells by gene manipulation or using specific
biocompatible materials (eg, hydrogel) to prevent the first
wave loss after injection. However, the use of these methods
in patients poses potential risks and side effects.
Recent reports on the interactions between MSCs and
Tregs appear favorable and may mitigate the loss of
MSCs after treatment.11,12 Tregs are a specialized subset
of T cells that facilitate self-tolerance and are known to
express both CD4 and CD25.26 The depletion of these Tregs
will spontaneously evoke autoimmune disease in otherwise
normal rodents, suggesting their major role in suppressing
the unfavorable immune response.26 Recently Tregs have
been reportedly related to tumor hypoxia, promoted
tolerance, and angiogenesis.12 Additionally, MSCs have
been found to interact with Tregs through interleukin 10,
prostaglandin E2, and transforming growth factor b, or by
cell-to-cell contact mechanisms.27 We sought to study the
interactions between the MSCs and Tregs once they were
cotransplanted in the ischemic myocardium. Our results
demonstrate that Tregs dramatically changed the behavior
of MSCs in vivo—the self-renewing rate was increased
evidenced by the shape of the cell clumps and the layers
of capsules, which usually characterize the fast growing
cells. Even though we cannot be certain of the degree of
benefit that the Tregs helped to prevent the early loss of
MSCs, it is clear that the Tregs aided in MSC survival
and self-renewal, as a result of their possible paracrine
effects. Because the Tregs we employed were autologous,
there were no immune rejection issues or other host versus
donor disease processes. In this study, we did not find
evidence showing the Tregs within the myocardial
environment caused any detrimental side effects. One
limitation of using Tregs is their very low number in
peripheral blood. To obtain Tregs in large numbers the na€ıve1136 The Journal of Thoracic and Cardiovascular SurTregs need to be expanded. Several protocols are available
for this purpose. Availability of a large number of Tregs will
allow better understanding of their role in improving MSC
function in myocardial recovery and regeneration.
Dhingra and colleagues28 recently reported that MSCs
stimulate the proliferation of Tregs through interaction
with CCL5 and CCL12. Tregs also increase the cell survival
of both allogeneic and syngeneic cells implanted into the
ischemic myocardium. Therefore, it is possible that
CD25þ cells surrounding the CD90þ cells in the heart
may be partially due to the endogenously recruited Tregs.
Furthermore, the combined group may have improved the
metabolic activity of the injected MSCs so that they
stimulated the production of more endogenous Tregs rather
than the survival of the injected Tregs. However in our study
no MSC clusters were found in the noninjected ischemic or
normal myocardial area. CD25þ cells were also not found
in the MSC-only sections. Therefore, our results suggest
that Treg and MSC interactions help both cell subsets’
survival after injection and possible recruitment of these
cells.
Tregs may play very important roles in the inhibition of
allogeneic reaction against transplanted MSCs.29 Thus,
using Tregs in allogeneic MSC transplantation needs to be
explored. Our study provides preliminary data within this
field. Functional improvement and cell-to-cell interaction
in vitro studies are still needed to confirm the true beneficial
effects of Tregs and to define their underlying mechanisms
of action.SUMMARY
This is the first in vivo study of autologous Treg andMSC
transplantation in a large animal model of myocardial
ischemia. We have shown here that autologous injection
of bone marrow–derived MSCs with freshly isolated and
purified Tregs is safe. No observable side effects or
abnormal cell proliferation was found in the cotransplanta-
tion study. This method of cotransplanting Tregs with
MSCs showed a beneficial effect on MSC survival and
self-renewing. The results from our study will help with
future clinical applications of cell-based therapy.References
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Dr Richard Weisel (Toronto, Ontario, Canada). Thank you
very much for an excellent presentation and congratulations to
your group for a very difficult study in these large animal
models. This study represents a real tour de force. The proposal
to enhance mesenchymal stem cell (MSC) engraftment is very
important. Another approach is to use the hydrogels that
were described earlier to improve cell survival. Another
alternative is to reduce the inflammatory phase, as Dr Mayer
discussed earlier, which is a very important concept. Of course
this is what MSCs do normally. The implantation of MSCs into
the heart induces the proliferation of T regulatory cells (Tregs),
1 of the major beneficial effects of MSC treatment. Therefore,
the transplantation of Tregs with MSCs is enhancing the
endogenous repair mechanisms that result from MSC therapy.
This approach is a great idea.
Did you actually improve MSC survival? Was the number of
MSCs in the heart greater with the Tregs?
Dr Zhou. These are good questions. It is difficult to
quantitatively count the total number of these cells at 6 weeks after
injection to see if they increased. However, evidence of an increase
includes the very dense and sphere-shaped clusters surrounded by
thin, layered capsules seen on serial tissue section analysis. These
were never found in the MSC-only injection heart. We believe the
cell number was increased compared with MSC only, but it’s
difficult to give a quantitative answer to this question.
Dr Weisel. Did you improve heart function?
DrZhou.This is preliminary data and this project is still ongoing.
Weare testing the functional improvement by performing stress echo
and magnetic resonance imaging before and after cell transplanta-
tion. The data will be shown in the near future.
Dr Weisel. The cotransplantation of Tregs and MSC was
beneficial for autologous cell therapy but may be very important
for allogeneic cell therapy. As you know, many investigators are
now proposing allogeneic rather than autologous cell therapy
because of the tremendous opportunity to have an off-the-shelf
product for patients who need it, particularly in the operating
room. Have you tried this approach for allogeneic cells?
Cotransplantation of Tregs and MSCs would be much more
relevant for allogeneic cell therapy.
Dr Zhou.We tried allogeneic cell therapy using green fluores-
cent cells and published those results previously. But during that
study we did not involve Tregs. I think it is an excellent idea to
do it in the future.diovascular Surgery c Volume 148, Number 3 1137
